Exploratory Study on mRNA Therapeutic Drug Targeting CD19 for the Treatment of Hematologic Malignancies

NCT07349849 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

47

Enrollment

OTHER

Sponsor class

Conditions

B-cell Malignancies

Interventions

DRUG: in vivo CAR-T drug based on LNP-mRNA

Sponsor

Xinqiao Hospital of Chongqing